Abstract
Background: Leukotriene (LT) E 4 and 8-isoprostane concentrations are elevated in exhaled breath condensate in children with asthma. The effects of leukotriene receptor antagonists (LTRAs) on exhaled leukotriene and prostanoids in children with asthma are unknown. Objective: (1) To study the effect of montelukast, a LTRA, on exhaled LTE 4, 8-isoprostane, and prostaglandin E 2 in children with asthma and atopic children; (2) to measure exhaled nitric oxide. Methods: An open-label study with oral montelukast (5 mg once daily for 4 weeks) was undertaken in 17 atopic children with asthma and 16 atopic children without asthma. Results: Pretreatment exhaled LTE 4 (P <.0001) and 8-isoprostane (P <.0001) values were higher in atopic children with asthma than in atopic children without asthma. In atopic children with asthma, montelukast reduced exhaled LTE 4 by 33% (P <.001), and this reduction was correlated with pretreatment LTE 4 values (r = -0.90; P = .0001). Posttreatment exhaled LTE 4 levels in children with asthma were higher than pretreatment LTE 4 values in atopic children without asthma (P <.004). Montelukast had no effect on exhaled LTE 4 in atopic children without asthma (P = .74), or on exhaled 8-isoprostane (atopic children with asthma, P = .94; atopic children without asthma, P = .55) and PGE 2 (atopic children with asthma, P = .56; atopic children without asthma, P = .93) in both groups. In atopic children with asthma, exhaled nitric oxide concentrations were reduced by 27% (P <.05) after montelukast. Conclusion: Leukotriene receptor antagonists decrease exhaled LTE 4 in atopic children with asthma. This reduction is dependent on baseline exhaled LTE 4 values. Clinical implications: Measurement of exhaled LTE 4 might help identify children with asthma most likely to benefit from LTRAs.
| Original language | English |
|---|---|
| Pages (from-to) | 347-353 |
| Number of pages | 7 |
| Journal | Journal of Allergy and Clinical Immunology |
| Volume | 118 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Aug 2006 |
Fingerprint
Keywords
- airway inflammation
- childhood asthma
- exhaled breath condensate
- exhaled nitric oxide
- Leukotriene E
- leukotriene receptor antagonists
- noninvasive markers
- prostanoids
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
Cite this
Effects of a leukotriene receptor antagonist on exhaled leukotriene E 4 and prostanoids in children with asthma. / Montuschi, Paolo; Mondino, Chiara; Koch, Pierluigi; Barnes, Peter J.; Ciabattoni, Giovanni.
In: Journal of Allergy and Clinical Immunology, Vol. 118, No. 2, 08.2006, p. 347-353.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effects of a leukotriene receptor antagonist on exhaled leukotriene E 4 and prostanoids in children with asthma
AU - Montuschi, Paolo
AU - Mondino, Chiara
AU - Koch, Pierluigi
AU - Barnes, Peter J.
AU - Ciabattoni, Giovanni
PY - 2006/8
Y1 - 2006/8
N2 - Background: Leukotriene (LT) E 4 and 8-isoprostane concentrations are elevated in exhaled breath condensate in children with asthma. The effects of leukotriene receptor antagonists (LTRAs) on exhaled leukotriene and prostanoids in children with asthma are unknown. Objective: (1) To study the effect of montelukast, a LTRA, on exhaled LTE 4, 8-isoprostane, and prostaglandin E 2 in children with asthma and atopic children; (2) to measure exhaled nitric oxide. Methods: An open-label study with oral montelukast (5 mg once daily for 4 weeks) was undertaken in 17 atopic children with asthma and 16 atopic children without asthma. Results: Pretreatment exhaled LTE 4 (P <.0001) and 8-isoprostane (P <.0001) values were higher in atopic children with asthma than in atopic children without asthma. In atopic children with asthma, montelukast reduced exhaled LTE 4 by 33% (P <.001), and this reduction was correlated with pretreatment LTE 4 values (r = -0.90; P = .0001). Posttreatment exhaled LTE 4 levels in children with asthma were higher than pretreatment LTE 4 values in atopic children without asthma (P <.004). Montelukast had no effect on exhaled LTE 4 in atopic children without asthma (P = .74), or on exhaled 8-isoprostane (atopic children with asthma, P = .94; atopic children without asthma, P = .55) and PGE 2 (atopic children with asthma, P = .56; atopic children without asthma, P = .93) in both groups. In atopic children with asthma, exhaled nitric oxide concentrations were reduced by 27% (P <.05) after montelukast. Conclusion: Leukotriene receptor antagonists decrease exhaled LTE 4 in atopic children with asthma. This reduction is dependent on baseline exhaled LTE 4 values. Clinical implications: Measurement of exhaled LTE 4 might help identify children with asthma most likely to benefit from LTRAs.
AB - Background: Leukotriene (LT) E 4 and 8-isoprostane concentrations are elevated in exhaled breath condensate in children with asthma. The effects of leukotriene receptor antagonists (LTRAs) on exhaled leukotriene and prostanoids in children with asthma are unknown. Objective: (1) To study the effect of montelukast, a LTRA, on exhaled LTE 4, 8-isoprostane, and prostaglandin E 2 in children with asthma and atopic children; (2) to measure exhaled nitric oxide. Methods: An open-label study with oral montelukast (5 mg once daily for 4 weeks) was undertaken in 17 atopic children with asthma and 16 atopic children without asthma. Results: Pretreatment exhaled LTE 4 (P <.0001) and 8-isoprostane (P <.0001) values were higher in atopic children with asthma than in atopic children without asthma. In atopic children with asthma, montelukast reduced exhaled LTE 4 by 33% (P <.001), and this reduction was correlated with pretreatment LTE 4 values (r = -0.90; P = .0001). Posttreatment exhaled LTE 4 levels in children with asthma were higher than pretreatment LTE 4 values in atopic children without asthma (P <.004). Montelukast had no effect on exhaled LTE 4 in atopic children without asthma (P = .74), or on exhaled 8-isoprostane (atopic children with asthma, P = .94; atopic children without asthma, P = .55) and PGE 2 (atopic children with asthma, P = .56; atopic children without asthma, P = .93) in both groups. In atopic children with asthma, exhaled nitric oxide concentrations were reduced by 27% (P <.05) after montelukast. Conclusion: Leukotriene receptor antagonists decrease exhaled LTE 4 in atopic children with asthma. This reduction is dependent on baseline exhaled LTE 4 values. Clinical implications: Measurement of exhaled LTE 4 might help identify children with asthma most likely to benefit from LTRAs.
KW - airway inflammation
KW - childhood asthma
KW - exhaled breath condensate
KW - exhaled nitric oxide
KW - Leukotriene E
KW - leukotriene receptor antagonists
KW - noninvasive markers
KW - prostanoids
UR - http://www.scopus.com/inward/record.url?scp=33746727618&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33746727618&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2006.04.010
DO - 10.1016/j.jaci.2006.04.010
M3 - Article
C2 - 16890757
AN - SCOPUS:33746727618
VL - 118
SP - 347
EP - 353
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
SN - 0091-6749
IS - 2
ER -